期刊文献+

深圳市龙岗区病毒性肝炎患者血清学分型监测分析

Results of serotyping of viral hepatiti patients in Longgang District,Shenzhen City
原文传递
导出
摘要 目的分析深圳市龙岗区病毒性肝炎患者血清学分型监测结果。方法采集静脉血5ml分离血清,-20℃保存。每2个月用冷藏车或者冰瓶专人送至市疾病预防控制中心急性传染病防治科检验室。用酶联免疫吸附法(ELISA)检测抗-HAV-IgM、HBsAg、抗-HBs、抗-HBc、抗HBcIgM、抗-HCV、抗HEVIgM等。结果抗-HAV-IgM总阳性检出率为1.55%,其中仅2002年为5.19%,其余年均为0。HBsAg总阳性检出率为34.44%,HBsAg+抗-HBc总阳性检出率为34.13%,HBsAg+抗HBcIgM总阳性检出率为5.56%,抗-HBcIgM总阳性检出率为13.21%。抗-HEVIgM总阳性检出率为8.17%,波动在1.90%~38.46%之间。未分型即总未检出率39.96%,波动在16.67%~60.00%之间。结论乙、丙型型肝炎仍然是目前重点防治的传染病。戊型肝炎的防治已经刻不容缓。 Objective To analyze the results of serotyping of viral hepatitis patients in Longgang District, Shenzhen City. Methods Veinous blood samples of 5ml were collected and stored at -20℃ and tested in Shenzhen Municipal Center for Diseae Control and Prevention. The levels of anti-HAV-IgM, HBsAg, anti-HBs, anti-HBc, anti-HBclg,anti-HCVand anti-HEVIgM were determined by ELISA and analyzed. Results The positive rate of anti-HAV-IgM was 1.55%, the total positive rate of HBsAg was 34.44%, the total positive rate of HBsAg+anti-HBe was 34.13%, whiloe that of HBsAg +anti- HBclgM and HBsAg +anti-HBelgM were 5.56% and 13.21%. The total positive rate of anti-HEVIgM was 8.17% . Conclusion Hepatitis B and C are currently the target infectious diseases in this district and the control of hepatitis E should also be carried out as quickly as possible.
出处 《中国热带医学》 CAS 2009年第2期356-357,共2页 China Tropical Medicine
关键词 病毒性肝炎 血清学分型 监测 Viral hepatitis Serotyping Monitoring
  • 相关文献

参考文献1

二级参考文献15

  • 1Alberti A, Benvegnu L. Management of hepatitis C. J Hepatol, 2003, 38(suppl 1)∶s1014-s1118.
  • 2Booth JCL, O'Grady J, Neuberger J. Clinical guidelines on the management of hepatitis C. Gut, 2001, 49(suppl 1)∶ s1-s21.
  • 3Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. Gut, 2002, 51∶864-869.
  • 4Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systemic review. Hepatology,2002,36(5 suppl 1)∶s135-s144.
  • 5Di Ciommo V, Russo P, Rava L, et al. Interferon alpha in the treatment of chronic hepatitis C in children: a meta-analysis. J Viral Hepat, 2003, 10∶210-214.
  • 6Fabrizi F, Dulai G, Dixit V, et al. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther, 2003, 18∶1071-1081.
  • 7Kjaergard LL, Krogsgaard K, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ, 2001, 323∶1151-1155.
  • 8National Institute of Health Consensus Development Conference Panel Statement. Management of hepatitis C. Hepatology, 2002, 36(5 suppl 1)∶s3-s20.
  • 9Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther, 2001, 15∶689-698.
  • 10Poynard T, McHutchison J, Davis GL, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology, 2000, 32∶1131-1137.

共引文献64

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部